| 摘要 |
FIELD: medicine.SUBSTANCE: group of inventions relates to field of medicine, namely to local application of therapeutic medications and (or) combination of therapeutic medications for preventions and treatment of vascular diseases, namely to intraluminal medical devices for local delivery of therapeutic medications and (or) combinations of therapeutic medications. bare metal stent with medication-releasing reservoirs, intended for implantation into tubular organ of live organism, includes elongated tubular construction, at least, one main composition layer and, at least, one covering composition layer. Elongated tubular construction has luminal surface and abluminal surface and includes multitude of interrelated elements. Segment of interrelated elements includes, at least, one reservoir, opening into luminal surface and abluminal surface. Composition of, at least, one main composition layer includes polymer, deposited in, at least, one reservoir, approached to luminal surface, and below abluminal surface of elongated tubular construction. Composition of, at least, one covering composition layer includes therapeutic agent, deposited in reservoir above main composition layer and below abluminal surface of elongated tubular construction. After implantation approximately 75% of abluminal surface are represented by bare metal and approximately 25% of abluminal surface are occupied by reservoirs, at least, partially filled with, at least, one main composition layer and said, at least, one covering composition layer. Approximately 90 days after implantation, at least, one main composition layer and, at least, one covering composition layer disappear completely. Upper surface of reservoir layer is located below abluminal surface of stent. In accordance with second version of stent implementation composition of , at least, one main composition layer includes co-polymer of lactic and glycolic acids (PLGA), and composition of , at least, one covering composition layer includes co-polymer of lactic and glycolic acids (PLGA), rapamycin and butyloxytoluene (BHT).EFFECT: inventions reduce potential risk of thrombosis and (or) embolism development and antirestenotic effect as a result of local delivery of medication.2 cl, 49 dwg, 10 tbl |
